Achieve Life Sciences (ACHV)
Develops cytisinicline for nicotine dependence across smoking-cessation and vaping-cessation programs.
Something off on this page? Send us feedback.
Develops cytisinicline, an investigational treatment for nicotine dependence. Its single operating segment covers development and potential commercialization, with operations in Canada, the United States, and the United Kingdom.
Develops cytisinicline, an investigational treatment for nicotine dependence. Its single operating segment covers development and potential commercialization, with operations in Canada, the United States, and the United Kingdom.
The lead smoking-cessation application received an FDA Complete Response Letter tied to observations at a prior third-party manufacturing facility and unfinished labeling. The company has said it intends to resubmit using Adare Pharma Solutions as primary manufacturer.
A separate vaping-cessation track has completed a Phase 2 study and an end-of-Phase-2 FDA meeting. The business remains dependent on FDA approval of cytisinicline, its only reportable product family.
Company facts
Target rangeAs of Sep 21, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Aug 13, 2026 | Morgan Stanley | Initiate | Rating: —Target: — | Target: $13 |
| Aug 12, 2026 | Raymond James | Reiterate | Rating: —Target: $20 | Target: $18 |
| Aug 12, 2026 | H.C. Wainwright | Reiterate | Rating: —Target: — | Target: $12 |
| Jun 26, 2026 | Raymond James | Target | Target: — | Target: $20 |
| Apr 20, 2026 | Canaccord Genuity | Target | Target: — | Target: $13 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $187.3M · Total debt $14.9M · Total assets $190.4M · Shareholders' equity −$14.7M
- Revenue
- $0
- Operating income
- −$18.4M
- Net income
- −$74.8M
No dividends on record.
| Institutions | ≈ 80.45% | 82.79M shares | |
|---|---|---|---|
| 119 holders · as of Jun 30, 2026 · largest filers plus last quarter's tail | |||
| Insiders | 0.94% | 966.0K shares | |
| 8 holders · as of Aug 21, 2026 | |||
| Strategic holders | 5.35% | 5.50M shares | |
| 1 holder · as of Aug 13, 2026 | |||
| Other | ≈ 13.26% | 13.65M shares | |
| remainder | |||
102.90M company shares as of Sep 22, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
This quarter's institutional total failed a plausibility check; shown: the largest filers plus last quarter's remainder.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
Frazier Life Sciences Management, L.P.Institution | 7.40% | 7.61M | as of Jun 30, 2026 |
TPG GP A, LLCInstitution | 6.68% | 6.88M | as of Jun 30, 2026 |
Frazier Life Sciences Public Fund, L.P.Institution | 6.44% | 6.63M | filed Apr 24, 2026 |
Venbio Partners LLCInstitution | 5.75% | 5.91M | as of Jun 30, 2026 |
JANUS HENDERSON GROUP Ltd.Strategic | 5.35% | 5.50M | filed Aug 13, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Aug 19, 2026 | Richard Alistair Stewart | director | −20,626 | $8.49 |
| Sep 18, 2025 | Richard Alistair Stewart | director, officer: Chief Executive Officer | −129,501 | $2.92 |
| Sep 18, 2025 | Mark K. Oki | officer: Chief Financial Officer | −50,060 | $2.92 |
- Dr. Reddy's Laboratories (ADR)
Global nicotine-replacement therapies for smoking and vaping cessation
- Teva (ADR)
Generic bupropion and varenicline options for smoking cessation
- Pfizer
Varenicline therapy for adult smoking cessation
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Achieve Life Sciences | $8.38 | +4.04% | $826.4M | — | — | — | — |
| Dr. Reddy's Laboratories (ADR) | $12.61 | +1.65% | $10.33B | 29.8 | 33.6 | 3.0 | −15.5% |
| Teva (ADR) | $39.53 | −1.32% | $46.66B | 66.8 | 14.1 | 2.7 | −0.8% |
| Pfizer | $27.85 | +0.40% | $158.10B | 36.7 | 9.9 | 2.5 | +2.6% |
| Median | 36.7 | 14.1 | 2.7 | −0.8% |